Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:24 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase IV Study in Drug-Naive Patients With T2DM in China
NCT03344341 · AstraZeneca · PHASE4 · terminated · last registry update 2021-12-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study overall progress behind of scheduled timeline. Study was terminated early due to company decision.” | – | Registry record, AstraZeneca |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC5A2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-11-01Phase 3 first posted: Beni-Suef University, Dapagliflozin 5 MG + Metformin Hydrochloride 1000 MG (NCT05601336)
- 2022-07-21Phase 3 first posted: The George Institute, Dapagliflozin 10mg Tab + Placebo (NCT05468203)
- 2022-06-22Phase 3 first posted: Ottawa Heart Institute Research Corporation, Canagliflozin + Placebo (NCT05427084)
- 2022-05-26Phase 3 first posted: Juntendo University, Empagliflozin 10 MG + Placebo (NCT05392764)
- 2022-05-16Phase 3 first posted: University Medical Center Groningen, Dapagliflozin 10 mg/day (oral) + Placebo (NCT05374291)
- 2022-04-11Phase 3 first posted: Oslo University Hospital, Dapagliflozin 10 mg + Placebo (NCT05321706)
- 2022-03-08Phase 3 first posted: Maria Sklodowska-Curie National Research Institute of Oncology, Empagliflozin 10 MG (NCT05271162)
- 2022-01-10Phase 3 first posted: National Institute of Cardiology, Warsaw, Poland, Empagliflozin 10 MG + Placebo (NCT05182658)
- 2021-12-30Phase 3 first posted: University of Oklahoma, Dapagliflozin 10Mg Tab + Placebo (NCT05174052)
- 2021-08-31Phase 3 first posted: EMS, PIEMONTE + EMPAGLIFLOZIN (NCT05028140)
- 2021-07-16Phase 3 first posted: University Health Network, Toronto, Dapagliflozin 10 MG Oral Tablet + Placebo Matching Dapagliflozin Oral Tablet (NCT04965935)
- 2020-12-17Phase 3 first posted: EMS, MADALENA ASSOCIATION + METFORMIN (NCT04670666)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision